Skip to main content
SpringerLink
Log in

Th1 type CD4+ T cells may be a potent effector against poorly immunogenic syngeneic tumors

Anti-tumor activity of Th1 type CD4+ T cells

  • Published:
Biotherapy

Abstract

We examined the possibility that Th1 type CD4+ T cells may be an effector against three kinds of syngeneic tumors such as highly immunogenic B16 melanoma (B16) and two poorly immunogenic lines of MCA fibrosarcoma (MCA) and 3LL carcinoma (3LL). In a proliferation assay, the Th1 type CD4+ T cell clone (MH2) recognized the purified protein derivatives (PPD) derived fromMycobacterium tuberculosis. In a tumor-neutralizing assay, MH2 showed anti-tumor activity against both B16 and MCA. In a model of pulmonary metastasis, MH2 also showed anti-tumor activity against both B16 and 3LL. In an assay of cytolysis, MH2 showed a moderate level of tumor necrosis factor-dependent cytolytic activity only against MCA. In a cytostasis assay, MH2 showed a high level of interferon γ-dependent cytostatic activity against the three tumors in the presence of macrophages. The anti-tumor activity of MH2 against B16 and 3LL was suggested to be, at least in part, attributable to the augmented natural killer activity. Taken together, these findings suggest that we may potentially be able to utilize Th1 type CD4+ T cells as an effector for immunotherapy against poorly immunogenic tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

PPD:

purified protein derivatives

SC:

spleen cells

MHC:

major histocompatibility complex

IFN:

interferon

TNF:

tumor necrosis factor

s.c:

subcutaneous(ly)

i.V.:

intravenous(ly)

CTLs:

cytotoxic T lymphocytes

MMC:

mitomycin C

IL:

interleukin

LAK:

lymphokine-activated killer

NK:

natural killer

mAb:

monoclonal antibody

References

  1. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. In: Dixon FJ, ed. Advance in immunology, Vol. 49. Academic press, 1991: 281–355.

  2. Hamaoka T, Fujiwara H. Phenotypically and functionally distinct T-cell subsets in anti-tumor responses. Immunol Today 1987; 8: 267–9.

    Google Scholar 

  3. Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988; 168: 1419–41.

    PubMed  Google Scholar 

  4. Shu S, Chou T, Rosenberg SA.In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J Immunol 1986; 136: 3891–8.

    PubMed  Google Scholar 

  5. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–21.

    PubMed  Google Scholar 

  6. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Schwartzentruber D, Wei JP, White DE. Immunotherapy of patients with metastatic melanoma using tumor-infiltrating lymphocytes and interleukin-2: preliminary report. N Eng J Med 1988; 319: 1676–80.

    Google Scholar 

  7. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991; 141: 729–37.

    Google Scholar 

  8. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714–25.

    PubMed  Google Scholar 

  9. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumors of spontaneous origin. Brit J Cancer 1976; 63: 241–9.

    Google Scholar 

  10. Mosmann TR, Schumacher JH, Street NF, Budd R, O'Garra A, Fong TAT, Bond MW, Moore KWM, Sher A, Fiorentino DF. Diversity of cytokine synthesis and function of mouse CD4+ Tcells. Immunol Rev 1991; 123: 209–29.

    PubMed  Google Scholar 

  11. Harada M, Matsuzaki G, Yoshikai Y, Kobayashi N, Kurosawa S, Takimoto H, Nomoto K. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma. Cancer Res 1993; 53: 106–11.

    PubMed  Google Scholar 

  12. Nagarkatti M, Clay SR, Nagarkatti PS. Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties. J Immunol 1990; 144: 4898–905.

    PubMed  Google Scholar 

  13. Maggi E, Parronchi P, Manetti R, Simonelli C, Piccinni M, Rugiu FS, Carli MD, Ricci M, Romagnani S. Reciprocal regulatory effects of IFN-γ and IL-4 on thein vitro development of human Th1 and Th2 clones. J Immunol 1992; 148: 2142–7.

    PubMed  Google Scholar 

  14. Montgomery AM., Wing MG, Lachmann PJ. The targeting of T-helper cells and tumourcidal macrophages to a B-cell lymphomausing a PPD-monoclonal antibody heteroconjugate. Immunology 1992; 75: 217–23.

    PubMed  Google Scholar 

  15. Winn MG, Montgomery AMP, Harley C, Lachmann PJ. Cytostasis of different tumours by a murine PPD-reactive CD4+ T lymphocyte clone is mediated by interferon-gamma and tumour necrosis factor alone or synergistically. Clin Exp Immunol 1990; 82: 208–13.

    PubMed  Google Scholar 

  16. Takatsu K, Hamaoka T, Tominaga A, Kanamasa Y. Augmented induction of tumor-specific resistance by priming withMycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells. J Immunol 1980; 125: 2367–73.

    PubMed  Google Scholar 

  17. Winn HJ. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homograft. J Immunol 1961; 86: 228–35.

    PubMed  Google Scholar 

  18. Kurosawa S, Harada M, Matsuzaki G, Shinomiya Y, Terao H, Kobayahsi N, Nomoto K. Early-appearing tumor-infiltrating natural killer cells play a crucial role in the generation of antitumor cytotoxic T lymphocytes. Immunol 1995; 85: 338–46.

    Google Scholar 

  19. Mitani M, Mori K, Himeno K, Matsumoto Y, Taniguchi K, Nomoto K. The role of cytostasis in tumor immunity: comparison between syngeneic and allogeneic systems. Cell Immunol 1985; 92: 22–30.

    PubMed  Google Scholar 

  20. Mitani M, Mori K, Himeno K, Nomoto K. Anti-tumor cytostatic mechanism and delayed-type heypersensitivity against a syngeneic murine tumor: comparison between neonatally thymectomized mice and congenitally athymic nude mice. J Immunol 1989; 142: 2148–54.

    PubMed  Google Scholar 

  21. People GE, Schoof DD, Andrews JVR, Goedegebuure PS, Eberlein TJ. T cell recognition of ovarian cancer. Surgery 1993; 114: 227–34.

    PubMed  Google Scholar 

  22. Lumsden AJ, Codde JP, Gray BN, van der Meide PH. Improved efficancy of Doxorubicin by simultaneous treatment with Interferon-γ and Interleukin-2. in vivo 1992; 6: 553–8.

    PubMed  Google Scholar 

  23. Stuehr DJ, Marletta MA. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or IFN-γ. J Immunol 1987; 139: 518–25.

    PubMed  Google Scholar 

  24. Farram E, Festenstein H. Mechanisms of “cytostasis” of tumors in vivo by syngeneic lymphoid cells of tumor bearers. Cell Immunol 1079; 44: 352–66.

    Google Scholar 

  25. Grimm EA, Mazumer A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–41.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Virology, Medical Institute of Bioregulation, Kyushu University, 812-82, Fukuoka, Japan

    Mamoru Harada

  2. Department of Immunology, Medical Institute of Bioregulation, Kyushu University, 812-82, Fukuoka, Japan

    Hiroshi Terao, Mamoru Harada, Shin Kurosawa, Yoshihiro Shinomiya, Tadao Okamoto, Osamu Ito, Hiroshi Sumichika, Mitsuhiro Takenoyama & Kikuo Nomoto

Authors
  1. Hiroshi Terao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mamoru Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shin Kurosawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshihiro Shinomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tadao Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Osamu Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroshi Sumichika
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mitsuhiro Takenoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kikuo Nomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Terao, H., Harada, M., Kurosawa, S. et al. Th1 type CD4+ T cells may be a potent effector against poorly immunogenic syngeneic tumors. Biotherapy 8, 143–151 (1994). https://doi.org/10.1007/BF01878498

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01878498

Key words

Search

Navigation